Qlucore - emergers.se

QLUCORE: Long term potential clouded by likely capital raise

2023-11-30• Analys, Research

With stable sales in H1’23/24, Qlucore has continued on the revised, more concentrated path announced in Q1, accompanied by a cost...

Read More →

QLUCORE: Streamlining focus to extend financial runway

2023-09-05• Analys, Research

In Q1’23/24, both sales of Qlucore Omics Explorer and costs were slightly higher than we expected. To extend its runway, Qlucore will...

Read More →

QLUCORE: Delayed CE approval suggests upcoming need for additional financing

2023-06-01• Analys, Research

With BSI as Notified Body, Qlucore now expects to obtain CE certification for its Qlucore Diagnostics ALL application in February 2025....

Read More →

QLUCORE: Important milestone passed on the road to a more individualized cancer care

2023-03-02• Analys, Research

The progress in Q3’22/23 (Nov–Jan) continues to support the long term case we’re seeing in Qlucore, where the company aims to provide...

Read More →

QLUCORE: Interview with CEO Carl-Johan Ivarsson about the important issues in 2023 and the revenue target of SEK 300 million in 2027

2023-02-01• Analys, Research

READ EMERGERS’ EQUITY RESEARCH ON QLUCORE HERE QLUCORE: At the vanguard of both oncology research and life science M&A With a strong...

Read More →

QLUCORE: At the vanguard of both oncology research and life science M&A

2023-01-20• Analys, Research

With a strong trend in oncology and life science R&D in favour of precision medicine, data analysis and AI, Qlucore is uniquely...

Read More →

QLUCORE: Structural growth story on track with a slight expansion of long-term scope

2022-11-30• Analys, Research

After the strong growth in Q1’22/23, sales bounced back in Q2’22/23, right in line with our forecast. With the process to CE marking of...

Read More →

QLUCORE: CE headwind overshadows structural growth story

2022-09-01• Analys, Research

While the business side of Qlucore is moving steady forward, with 67% growth, two new Qlucore Insight license deals and an expansion of the...

Read More →

QLUCORE | Intervju med vd Carl-Johan Ivarsson om utsikterna för Diagnostics och intäktsmålet på 300 MSEK 2026

2022-06-02• Okategoriserade

Med en försäljningstillväxt på 9% under 2021/22 (Maj-April) ligger fokus på Qlucore nu på CE-märkningen av Diagnosticsplattformen...

Read More →

QLUCORE: Expanding pipeline of precision diagnostics projects

2022-05-31• Analys, Research

With sales consisting of the data analytics software Omics Explorer, Qlucore reported revenue growth of 9% for the full year 2021/22...

Read More →

Etikett: Qlucore

QLUCORE: Long term potential clouded by likely capital raise

QLUCORE: Streamlining focus to extend financial runway

QLUCORE: Delayed CE approval suggests upcoming need for additional financing

QLUCORE: Important milestone passed on the road to a more individualized cancer care

QLUCORE: Interview with CEO Carl-Johan Ivarsson about the important issues in 2023 and the revenue target of SEK 300 million in 2027

QLUCORE: At the vanguard of both oncology research and life science M&A

QLUCORE: Structural growth story on track with a slight expansion of long-term scope

QLUCORE: CE headwind overshadows structural growth story

QLUCORE | Intervju med vd Carl-Johan Ivarsson om utsikterna för Diagnostics och intäktsmålet på 300 MSEK 2026

QLUCORE: Expanding pipeline of precision diagnostics projects

ActionETFs.com

CONTACT